Press Releases Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
2.77 ^USD	+2.21%		+1.09%	+42.78%

May. 06	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT
May. 06	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lyell Immunopharma to Participate in BofA Securities Health Care Conference	May. 07	GL
Lyell Immunopharma: Q1 Earnings Snapshot	May. 06	AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024	May. 06	GL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	Mar. 05	GL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	Feb. 28	GL
Lyell Immunopharma Announces Participation in March Investor Conferences	Feb. 26	GL
Lyell Immunopharma Announces Participation in March Investor Conferences	Feb. 26	AQ
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma	Nov. 09	GL
Lyell Immunopharma: Q3 Earnings Snapshot	Nov. 07	AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023	Nov. 07	GL
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors	Nov. 04	PU
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time	Nov. 03	PU
SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming	Nov. 03	PU
SITC 2023: Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies	Nov. 03	PU
SITC 2023: Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors	Nov. 03	PU
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing	23-10-31	GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	23-09-27	GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	23-09-27	AQ
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell s CAR T-Cell Therapy on Cellares Cell Shuttle Platform	23-09-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Press Releases

Filters